Arrowhead Research Corporation (ARWR) Begins Dosing In Phase 2a Trial Of RNAi Therapeutic ARC-520 In Chronic Hepatitis B Patients
3/24/2014 7:44:17 AM
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that patient dosing has begun in a Phase 2a clinical trial of ARC-520, its RNAi therapeutic for the treatment of chronic hepatitis B virus (HBV) infection. The study is planned to enroll up to 16 chronic HBV patients in two dose cohorts with patients receiving either ARC-520 or placebo in combination with entecavir. The study is designed to evaluate the depth and duration of hepatitis B surface antigen (HBsAg) decline, among other measures, in response to a single dose of ARC-520. The Company anticipates planned enrollment to be complete in the second quarter of 2014 and expects top line results to be released in the third quarter.
Help employers find you! Check out all the jobs and post your resume.
comments powered by